Success Story: Advancing Evidence-Based Treatment Strategies for Metabolic Liver Disease: NIW Approval Secured for a Clinical Epidemiology Researcher from Nigeria
Client’s Testimonial:
"Thrilled that my EB-2 NIW (I-140) has been approved! Working with Chen Immigration Law Associates made this intense process incredibly smooth and manageable. Their team was exceptionally thorough, highly professional, and strategic in defining my proposed endeavor. They provided clear timelines and meticulous feedback on my reference/testimonial letters and petition letter, leaving no room for ambiguity. I highly recommend the Chen team to anyone looking for top-tier NIW expertise.”
On September 2nd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a PGY-1 Resident in the Field of Clinical Epidemiology (Approval Notice).
General Field: Clinical Epidemiology
Position at the Time of Case Filing: PGY-1 Resident
Country of Origin: Nigeria
State of Residence at the Time of Filing: New York
Approval Notice Date: September 2nd, 2026
Processing Time: 2 months (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of a clinical epidemiology researcher whose work advances evidence-based treatment strategies for metabolic liver disease. The client’s proposed endeavor focuses on conducting retrospective cohort studies using large-scale healthcare databases, statistical methods, and real-world clinical data to evaluate biliary outcomes associated with metabolic therapies for patients with metabolic dysfunction-associated steatohepatitis (MASH).
At the time of filing, the client was conducting research in clinical epidemiology, focusing on real-world outcomes research, healthcare data analysis, and evidence-based approaches for improving clinical decision-making.
Research with National Importance
The client’s research addresses important healthcare challenges related to the growing burden of metabolic liver disease by generating evidence on treatment safety, effectiveness, and long-term outcomes. By analyzing real-world patient data and evaluating risks associated with emerging metabolic therapies, his work supports more informed treatment selection, improved patient safety, and more effective management of MASH.
These contributions align with U.S. priorities in healthcare innovation, evidence-based medicine, biotechnology, and improving outcomes for patients with chronic diseases.
Academic Contributions and Recognition
At the time of filing, the client had authored 3 peer-reviewed journal articles (1 first-authored) and 1 conference abstract. His published work received 26 citations, demonstrating recognition from researchers studying clinical outcomes, chronic disease management, and evidence-based healthcare strategies.
His publications appeared in recognized medical journals, including The Journal of Clinical Endocrinology & Metabolism. Two of his publications ranked among the top 10% most cited articles in Clinical Medicine for their respective years of publication. He has also completed at least 1 peer review for a journal in his field, reflecting recognition of his expertise by the research community.
Recognition from Experts
Experts highlighted the client’s ability to apply clinical knowledge and epidemiological methods to address important healthcare challenges.
One expert noted:
“His extensive educational background and medical experience have left him well-positioned to conduct large-scale epidemiological research based on clinical observations, which he is using to improve treatments for a range of conditions plaguing patients across the United States.”
This endorsement reinforces the significance of the client’s clinical epidemiology research. Combined with his publication record, citation impact, peer review activity, and medical expertise, the expert support further demonstrates his ability to advance evidence-based healthcare strategies.
NIW Approval and Outlook
The I-140 NIW petition was filed on July 2nd, 2026, with Direct Premium Processing, and approved on September 2nd, 2026. The approval recognized the national importance of the client’s work in clinical epidemiology, particularly his efforts to generate real-world evidence on metabolic therapies and biliary outcomes to improve clinical decision-making for MASH patients.
This outcome supports the client’s continued efforts to advance clinical research, evidence-based medicine, and data-driven healthcare solutions in the United States. We congratulate him on this approval and wish him continued success in advancing medical research.